Cartography Biosciences
South San Francisco, California, United States · Biotechnology · 63 employees
Cartography Biosciences is building a differentiated oncology pipeline of antibody-based therapies designed to target tumors more precisely than existing therapeutics. Cartography’s ATLAS and SUMMIT drug discovery platforms are powered by an industry-leading, fully integrated dataset spanning hundreds of thousands of cell states across the healthy body and large-scale profiling of individual cells
Funding history
- Series series b — $67.0M — Oct 2025
Recent signals
- May 07, 2026: Raised funding
- May 07, 2026: Samsung Life Science Fund partners with Cartography Biosciences to enhance genomic data-based drug development.
- Jan 06, 2026: Cartography Biosciences Forms Strategic Agreement with Pfizer for Tumor-Selective Antigens Discovery.
- Oct 02, 2025: Raised $67.0M in Series series b
- Feb 07, 2024: Cartography Biosciences Expands Leadership Team with Appointment of Dan Rock, Ph.D., as Chief Scientific Officer to Advance Novel Oncology Programs into Clinic
See plans & pricing → Track Cartography Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.